BMS’s oral AML therapy Onureg receives EU approval

Onureg is the oral version of Vidaza, two of the drugs BMS gained as part of its acquisition of Celgene in 2019. ... Onureg is the oral version of Vidaza, two of the drugs BMS gained as part of its acquisition of Celgene for $74bn in 2019.

BMS links up with Exscientia for $1.2bn AI drug discovery deal

The new deal builds on BMS’ existing collaboration with Exscientia, initiated in 2019 with Celgene prior to the company’s acquisition by BMS.

Building meaningful customer engagement through data-driven digital insights

An example of successful digital engagement can be seen in Celgene’s initiative to launch a hashtag, #PancChat, together with patient advocacy group Let’s Win!

FDA approves BMS’ blood cancer CAR T therapy after delay

BMS acquired Breyanzi following its $74bn takeover of Celgene in 2019 – the CAR-T therapy is one of the key assets critical to the potential payout of the merger in contingent ... As part of the merger agreement, BMS agreed to make a series of

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]